Program Opens to Expand Patient Access to Niraparib for Ovarian Cancer
January 19th 2017TESARO, manufacturer of the PARP inhibitor niraparib has opened an expaned access program (EAP) for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after complete or partial response to platinum-based chemotherapy.
Treatment Informed by PET Imaging Linked to Better Response Rates in Esophageal Cancer
January 18th 2017Patients with esophogeal cancers who received induction chemotherapy, followed by PET imaging to determine whether alternative chemotherapy was needed had improved pathologic complete response rates
Cognitive Impairment in Breast Cancer a Substantial Problem, Study Finds
January 16th 2017A recent study aimed to determine the when and why chemotherapy-induced cognitive impairment, or chemobrain, occurs, who is most likely to develop it, and whether certain factors (such as age, race, menopausal status, etc) play any role.